Dementia Nervous System Diseases Dementia
Conditions
Interventions
1. The active intervention will be concentrated, standardised Ginkgo biloba extract (25% active Ginkgo-flavoneglycosides), prepared according to accepted guidelines in a 60 mg tablet (EGB-761, Schwabe
Sponsors
Alzheimer's Society (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 55 years and over 2. Clinician's diagnosis of dementia 3. Presence of a carer 4. Consent of patient and carer 5. Sufficient command of English to complete questionnaires 6. Mini Mental State Examination (MMSE-23) score of 15 - 24
Exclusion criteria
Exclusion criteria: 1. Commencement of acetylcholinesterase therapy within two months of recruitment 2. Current anticoagulant therapy 3. Abnormal clotting profile
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-cog) at six months. | — |
Secondary
| Measure | Time frame |
|---|---|
| All at six months: 1. Participant: Quality of Life scale in Alzheimer?s disease (QoL-AD), Neuropsychiatric Inventory questionnaire (NPI), Geriatric Evaluation by Relative's Rating Instrument (GERRI), adverse events 2. Carer: European Quality of life questionnaire (EQ-5D), Zarit caregiver Burden Interview (ZBI) | — |
Countries
United Kingdom
Outcome results
None listed